Patent Law Weblog
recent posts
- Ex parte Chowdhury (PTAB 2026)
- Biofer S.P.A. v. Vifor (International) AG (Fed Cir. 2026)
- Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026)
- Patentees File Claim under 28 U.S.C. § 1498 before Court of Federal Claims, and Federal Government Files Motion to Dismiss under 28 U.S.C. § 1500
- Amici Address Section 1498 Scope in Moderna COVID-19 Infringement Appeal: In Favor of Reversal
about
Category: Written Description
-
By Donald Zuhn — In an appeal from a decision of the Board of Patent Appeals and Interferences, the Federal Circuit affirmed the rejection of claims directed to isolated DNA molecules encoding TNF binding protein II (TBP-II) under the written description requirement of 35 U.S.C. § 112. Appellants had purified TBP-II from urine…
